Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1981 Aug;20(2):197–203. doi: 10.1128/aac.20.2.197

Mezlocillin: tentative interpretive standards for disk diffusion susceptibility testing.

P C Fuchs, A L Barry, C Thornsberry, R N Jones, E H Gerlack
PMCID: PMC181663  PMID: 6456689

Abstract

The susceptibility of 447 clinical bacterial isolates to mezlocillin and carbenicillin was tested by standardized agar disk diffusion and reference broth micro-dilution methods. Tentative interpretive criteria for disk susceptibility testing by using 75 micrograms mezlocillin disks are proposed: susceptible, greater than or equal to 16 mm; indeterminate, 13 to 15 mm; and resistant, less than or equal to 12 mm. These would be applicable to both Pseudomonas species and the Enterobacteriaceae, but not to Staphylococcus aureus. For S. aureus, the breakpoints for susceptible, greater than or equal to 29 mm, and resistant, less than or equal to 28 mm, hold for mezlocillin as well as for the other penicillinase-susceptible penicillins.

Full text

PDF
197

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Thornsberry C., Badal R. E., Baker C. N., Jones R. N., Gerlach E. H. Piperacillin susceptibility tests by the single-disk agar diffusion technique. Antimicrob Agents Chemother. 1979 Sep;16(3):378–385. doi: 10.1128/aac.16.3.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bergan T., Brodwall E. K., Wiik-Larsen E. Mezlocillin pharmacokinetics in patients with normal and impaired renal functions. Antimicrob Agents Chemother. 1979 Nov;16(5):651–654. doi: 10.1128/aac.16.5.651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bergan T. Pharmacokinetics of mezlocillin in healthy volunteers. Antimicrob Agents Chemother. 1978 Dec;14(6):801–806. doi: 10.1128/aac.14.6.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bodey G. P., Pan T. Mezlocillin: in vitro studies of a new broad-spectrum penicillin. Antimicrob Agents Chemother. 1977 Jan;11(1):74–79. doi: 10.1128/aac.11.1.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fu K. P., Neu H. C. Azlocillin and mezlocillin: new ureido penicillins. Antimicrob Agents Chemother. 1978 Jun;13(6):930–938. doi: 10.1128/aac.13.6.930. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fuchs P. C., Thornsberry C., Barry A. L., Gavan T. L., Gerlach E. H., Jones R. N. Ticarcillin, carbenicillin and BL-P1908. In vitro comparison of three anti-pseudomonal semisynthetic penicillins. J Antibiot (Tokyo) 1977 Dec;30(12):1098–1106. doi: 10.7164/antibiotics.30.1098. [DOI] [PubMed] [Google Scholar]
  7. Issell B. F., Bodey G. P. Mezlocillin for treatment of infections in cancer patients. Antimicrob Agents Chemother. 1980 Jun;17(6):1008–1013. doi: 10.1128/aac.17.6.1008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Issell B. F., Bodey G. P., Weaver S. Clinical pharmacology of mezlocillin. Antimicrob Agents Chemother. 1978 Feb;13(2):180–183. doi: 10.1128/aac.13.2.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Matsen J. M., Lund M. E., Brooker D. C. Comparison and evaluation of carbenicillin disks in diffusion susceptibility testing. Antimicrob Agents Chemother. 1974 Jun;5(6):599–606. doi: 10.1128/aac.5.6.599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Metzler C. M., DeHaan R. M. Susceptibility tests of anaerobic bacteria: statistical and clinical considerations. J Infect Dis. 1974 Dec;130(6):588–594. doi: 10.1093/infdis/130.6.588. [DOI] [PubMed] [Google Scholar]
  11. Pancoast S. J., Neu H. C. Kinetics of mezlocillin and carbenicillin. Clin Pharmacol Ther. 1978 Jul;24(1):108–116. doi: 10.1002/cpt1978241108. [DOI] [PubMed] [Google Scholar]
  12. Parry M. F., Neu H. C. Comparison and evaluation of ticarcillin and carbenicillin using disk diffusion methods. Antimicrob Agents Chemother. 1976 Apr;9(4):625–632. doi: 10.1128/aac.9.4.625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Phaneuf D., Neu H. C. Agar disk diffusion susceptibility characteristics of azlocillin, carbenicillin, mezlocillin, piperacillin, and ticarcillin. Antimicrob Agents Chemother. 1979 Nov;16(5):625–630. doi: 10.1128/aac.16.5.625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Thadepalli H., Rao B. Clinical evaluation of mezlocillin. Antimicrob Agents Chemother. 1979 Nov;16(5):605–610. doi: 10.1128/aac.16.5.605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Verbist L. Comparison of the activities of the new ureidopenicillins piperacillin, mezlocillin, azlocillin, and Bay k 4999 against gram-negative organisms. Antimicrob Agents Chemother. 1979 Aug;16(2):115–119. doi: 10.1128/aac.16.2.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. White G. W., Malow J. B., Zimelis V. M., Pahlavanzadeh H., Panwalker A. P., Jackson G. G. Comparative in vitro activity of azlocillin, ampicillin, mezlocillin, piperacillin, and ticarcillin, alone and in combination with an aminoglycoside. Antimicrob Agents Chemother. 1979 Apr;15(4):540–543. doi: 10.1128/aac.15.4.540. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES